METTL3 and hepatocellular carcinoma: High expression of METTL3 has been reported to be an oncogene in multiple solid tumors, such as hepatocellular carcinoma (HCC) (51), non-small cell lung cancer (NSCLC) (52), gastric cancer (GC) (53), colorectal cancer (CRC) (54), and bladder cancer (BLC) (55).